Current report No. 2/2022 – Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression
11 January 2022 | Current reports
In reference to current report No. 52/2021, the Management Board of Celon Pharma S.A. (“Company”) hereby informs that on January 10, 2022 it received specifications of European patents No. EP 3 731 815 B1 and EP 3 505 157 B1 for esketamine inhalation formulation, the granting of which was announced in “European Patent Bulletin 21/49” of December 8, 2021.
Welcome to Celon Pharma S.A.
Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. The company is also a successful marketing authorisation holder for it products. The drugs we offer help thousands of patients lead a better and longer life.
News
- Current report No. 2/2022 – Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depressionIn reference to current report No. 52/2021, the Management Board of Celon Pharma S.A. (“Company”) hereby informs that on January 10, 2022 it received specifications of European patents No. EP 3 731 815 B1 and EP 3 505 157 B1 for esketamine inhalation formulation, the granting of which was announced in “European Patent Bulletin 21/49” of December 8, 2021.
- Current report No. 1/2022 – Dates for submitting periodical reports in 2022Acting pursuant to Article 80 subs. 1 of the Regulation of the Minister of Finance of 29 March 2018 on current and periodic information provided by issuers of securities [...], the Management Board of Celon Pharma S.A. announces the dates for submitting periodical reports in 2022
- Current report No. 55/2021 – Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd.In connection with current report No. 13/2021 K on Celon Pharma S.A. (“Company”) and Glenmark Pharmaceuticals Ltd with its registered seat in India concluding a licence
Research and development
We create innovative drugs, that will change the lives of patients globally
Products
We are leaders in
inhalation technology
